Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 3/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.38 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.37 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386706 | 1.00 | KDM4E (0.41) | KDM4EMEN1KMT2ALMNATHRB | |
| SCHEMBL5845014 | 0.89 | KDM4E (0.39) | KDM4EMEN1KMT2ALMNATHRB | |
| SCHEMBL6681140 | 0.87 | KDM4E (0.38) | KDM4EMEN1KMT2ALMNATHRB | |
| SCHEMBL8486988 | 0.84 | KDM4E (0.62) | KDM4EERN1SLC9A1MTNR1BMTNR1A | |
| SCHEMBL8486991 | 0.84 | KDM4E (0.62) | KDM4EERN1SLC9A1MTNR1BMTNR1A | |
| SCHEMBL6678740 | 0.83 | MEN1 (0.37) | KDM4EMEN1KMT2ALMNATHRB | |
| SCHEMBL12809257 | 0.82 | CDK4 (0.42) | KDM4EMEN1KMT2ALMNAITGB2 | |
| SCHEMBL334471 | 0.80 | ITGB2 (0.39) | KDM4EMEN1KMT2ALMNAITGB2 | |
| SCHEMBL1649253 | 0.77 | KCNJ1 (0.47) | KDM4EMEN1KMT2ALMNATHRB | |
| SCHEMBL20741937 | 0.76 | ERN1 (0.41) | MEN1KMT2ALMNATHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106588841-B | The method for synthesizing 2,3- dihydro -1- benzofuran -4- formaldehyde | 富乐马鸿凯（大连）医药有限公司 | 2019-01-25 | — | — | CN | claimed |
| CN-106588841-A | Synthesis method of 2,3-dihydro-1-benzofuran-4-carbaldehyde | 大连鸿凯化工科技发展有限公司 | 2017-04-26 | — | — | CN | claimed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220389021-A1 | INHIBITORS OF KRAS G12C | BEONE MEDICINES I GMBH (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| CN-114929706-A | Inhibitors of KRAS G12C | 百济神州有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022111498-A1 | PYRIMIDINEDIONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2022-06-02 | — | — | WO | disclosed |
| EP-1027043-A4 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2002-02-20 | — | — | EP | disclosed |
| EP-1041980-A1 | ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1027043-A1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | Bristol-Myers Squibb Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6060506-A | FOR TREATMENT OF SLEEP DISORDERS, CIRCADIAN RHYTHM DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| US-6011059-A | PREVENTING OR TREATING ANGINA PECTORIS, CARDIAC DYSFUNCTION, MYOCARDIAL NECROSIS, AND ARRHYTHMIA EMPLOYING THE ABOVE ACYL GUANIDINES. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| US-5981571-A | USEFUL AS MELATONERGIC AGENTS IN THE TREATMENT OF SLEEP DISORDERS, SEASONAL DEPRESSION, SHIFTS IN CIRCADIAN CYCLES, MELANCHOLIA, STRESS, APPETITE REGULATION, BENIGN PROSTATIC HYPERPLASIA AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| WO-1999033460-A1 | ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-07-08 | — | — | WO | disclosed |
| US-5856529-A | ADJUSTMENT OF NERVOUS SYSTEM, ENDOCRINE FUNCTION; REPRODUCTION, BODY WEIGHT AND METABOLISM | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1998025606-A1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | KDM4E 576/4885MEN1 3166/4885KMT2A 1040/4885 |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KDM4E 3093/4885MEN1 676/4885KMT2A 589/4885 |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | KDM4E 722/4885MEN1 750/4885KMT2A 1815/4885 |
| US-20220389021-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KDM4E 3634/4885MEN1 895/4885KMT2A 2234/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | KDM4E 722/4885MEN1 750/4885KMT2A 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.